Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile

June 13, 2025

EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter • Psychedelic Alpha at Psychedelic Science 2025 • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile • and more…

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

June 12, 2025

Explore or interactive database of psychedelic patent activity in May 2025 via our Pα+ interface. We also cover a handful of related headlines: from Gilgamesh Pharmaceuticals’ IP around its lead candidate, GM-2505, through to new published applications from Reconnect Labs that claim compositions of 5-MeO-DMT.

Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100

June 6, 2025

The Class of Bulletin #100: Where Are They Now? • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent? • A Closer Look at atai’s Potential Acquisition of Beckley Psytech • Q1’25 Psychedelic Lobbying Update • Holy Trips and Hot Takes: Religious Leaders Study Finally Published • and much, much more…

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

June 2, 2025

Psychedelic drug developers atai Life Sciences and Beckley Psytech are set to merge in a transaction that would value Beckley at around $370M. The combined entity, which would be named atai Beckley, would have a leadership team and Board reflective of both companies. Psychedelic Alpha spoke with sources close to the companies to learn more about the proposed merger and financing.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more